Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

AstraZeneca’s Farxiga Label Includes, But Downplays, Bladder Cancer Risk

Jan 13 2014

• By Emily Hayes

Related Content

Big Pharma Tries Out New Class On The Diabetes Block: SGLT-2

Jul 01 2009

Is BMS/AstraZeneca's Dapagliflozin More Than Just Another Oral Diabetes Drug?

Oct 02 2009

AstraZeneca’s R&D Restructuring Follows Hot Spot Trend

Mar 18 2013

Dapagliflozin’s CV Profile Shines, But FDA Panel Review Falls On Cancer Concerns

Jul 25 2011

FDA Panel Questions Role Of CV Safety Meta-Analyses At Dapagliflozin Review

Dec 23 2013

Dapagliflozin’s Commercial Appeal Could Dim With Bladder Cancer Concerns

Dec 23 2013

AZ Doubles Down On Diabetes, Buys Out Bristol’s Share in Alliance

Dec 23 2013

Related Companies

AstraZeneca PLC

Bristol Myers Squibb Company

Johnson & Johnson

Merck & Co., Inc.

Eli Lilly and Company

Boehringer Ingelheim GmbH

Pfizer Inc.

Additional Topics

Clinical Trials Regulation Approvals

More from Clinical Trials

More from R&D

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window